Cancer最新文献

{"title":"The quality of patient decision aids for lung cancer screening: Results from an environmental scan","authors":"Robert J. Volk PhD,&nbsp;Jessica S. Lettieri MPH,&nbsp;Viola B. Leal MPH,&nbsp;Gabrielle F. Duhon MPH, CHES,&nbsp;Kristin G. Maki PhD,&nbsp;M. Priscila Bernal Brietzke PhD,&nbsp;Naomi Q. P. Tan PhD,&nbsp;Elisa E. Douglas PhD, MSPH,&nbsp;Sarah Coles MD,&nbsp;Mark H. Ebell MD, MS,&nbsp;Maria C. Mejia MD, MPH,&nbsp;Ella A. Kazerooni MD, MS,&nbsp;Lauren Rosenthal MPH,&nbsp;Robert A. Smith PhD","doi":"10.1002/cncr.70008","DOIUrl":"10.1002/cncr.70008","url":null,"abstract":"<p>Shared decision making is recommended for lung cancer screening (LCS) by professional organizations and payers. Patient decision aids can be used to support shared decision making, but they need to meet quality standards to minimize the potential for biased and poorly informed patient decisions. After the updated LCS recommendation from the US Preventive Services Task Force in 2021, the authors conducted an environmental scan of public-facing patient educational materials and evaluated them against criteria from the International Patient Decision Aid Standards for high-quality patient decision aids. The Google site search function was used to search websites from National Cancer Institute-funded cancer centers, professional societies, patient advocacy groups, cancer coalitions, and private organizations for educational materials on LCS. A general web search using Google, Google Scholar, and select databases was also conducted. Considerations unique to the LCS context (e.g., the importance of annual screening and smoking cessation) were documented. The search identified 96 educational materials that included information about both benefits and harms of LCS. Of these, 39 did not meet qualifying criteria for decision aids, with failure to explicitly identify LCS as a decision being the primary reason for exclusion. Only 10 of the remaining decision aids met quality criteria from the International Patient Decision Aid Standards. These aids emphasized that LCS should be performed annually, most avoided stigmatizing language, and several included personalization features using prediction models. Clinicians and patients can be confident in using these high-quality aids to complement the process of shared decision making for LCS. Validated aids in languages other than English and Spanish are needed.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes show a reduction in treatment failure associated with dose-escalated, hypofractionated radiation therapy for localized prostate cancer","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.70013","DOIUrl":"10.1002/cncr.70013","url":null,"abstract":"<p>Long-term results of a phase 3 randomized trial comparing conventionally fractionated intensity-modulated radiation therapy (CIMRT) with dose-escalated, hypofractionated intensity-modulated radiation therapy (HIMRT) in patients with localized prostate cancer found considerable improvement in treatment failure rates among patients treated with HIMRT versus CIMRT according to a study published in the <i>Journal of Clinical Oncology</i>.<span>¹</span></p><p>The findings add to the growing body of evidence supporting the use of hypofractionated IMRT and making it the current standard of care. Data from the current study show that at a median follow-up of 13.2 years, men undergoing HIMRT had less frequent treatment failure than those undergoing CIMRT (11% vs. 21%). The result shows improvement but was not statistically significant. When the analysis was limited to patients who did not receive androgen deprivation therapy (ADT), patients treated with HIMRT showed a significant improvement in treatment failure in comparison with patients treated with CIMRT (13% vs. 26%; <i>p</i> = .039).</p><p>The study also found that long-term distant metastases were rare and occurred primarily in the intermediate-risk cohort treated with CIMRT or HIMRT (8% vs. 4%).</p><p>A total of 222 patients with localized prostate cancer were included in the trial; 206 of the patients were evaluable. Most patients had intermediate-risk disease (71%), 90% had a PSA level ≤10 ng/mL, 48% had Gleason grade 2 disease, and 24% received ADT. Patients were randomized to CIMRT (<i>n</i> = 102) or HIMRT (<i>n</i> = 104). Patients treated with CIMRT received 75.6 Gy in 42 fractions (1.8 Cy per fraction) over 8.4 weeks. Patients treated with HIMRT received 72 Gy in 30 fractions (2.4 Gy per fraction) over 6 weeks.</p><p>The results build on an initial assessment of the trial at a median follow-up of 9.5 months that showed 8-year failure rates of 10.7% with HIMRT and 15.4% with CIMRT.<span>²</span> Similar to the initial results, the long-term results showed no statistically significant difference between HIMRT and CIMRT in grade 2 or higher late gastrointestinal adverse effects (10% vs. 4% at 10 years, <i>p</i> = .09) or grade 2 or higher genitourinary adverse effects (26% vs. 23% at 10 years, <i>p</i> = .5).</p><p>“These data represent one of the largest follow-ups published so far for hypofractionated regimens and provide the most robust long-term data on the safety and tolerability of hypofractionated regimens in prostate cancer, while potentially indicating that dose-escalated, shorter courses of radiation for prostate cancer may provide higher efficacy than traditional, conventionally fractionated radiation,” says the lead author of the study, Comron Hassanzadeh, MD, MPH, an assistant professor of genitourinary radiation oncology at The University of Texas MD Anderson Cancer Center.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab","authors":"Yasunori Yoshino MD,&nbsp;Akiko Furusawa MD, PhD,&nbsp;Katsuhiko Nara PharmD,&nbsp;Ayumi Taguchi MD, PhD,&nbsp;Masako Ikemura MD, PhD,&nbsp;Hideo Arai MD, PhD,&nbsp;Tsubasa Hiraki MD, PhD,&nbsp;Aya Ishizaka MD,&nbsp;Saki Tsuchimochi MD, PhD,&nbsp;Harunori Honjoh MD, PhD,&nbsp;Naoyuki Miyasaka MD, PhD,&nbsp;Yasuyuki Hirashima MD, PhD,&nbsp;Kenbun Sone MD, PhD,&nbsp;Nao Kino MD, PhD","doi":"10.1002/cncr.70071","DOIUrl":"10.1002/cncr.70071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Platinum-resistant (PR) ovarian clear cell carcinoma (OCCC) is highly resistant to chemotherapy and has a poor prognosis. Both in-vitro and clinical studies have suggested that gemcitabine (GEM) is particularly effective against OCCC. Moreover, a combination with bevacizumab (Bev) is expected to enhance the efficacy of chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To clarify these effects, the authors conducted a multicenter, retrospective cohort study of 130 patients who received treatment single-agent chemotherapy, with or without Bev, for PR-OCCC. The effects of loss of AT-rich interaction domain 1A (ARID1A) protein expression also were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients who received GEM as their first regimen achieved better overall survival (OS) than those who received other agents (median OS, 15.2 vs. 11.0 months; hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.41–0.96; <i>p</i> = .032). Bev combination therapies demonstrated a significantly improved time to treatment failure compared with chemotherapy alone (6.6 vs. 2.7 months; HR, 0.61; 95% CI, 0.41–0.87; <i>p</i> = .009) and showed a trend toward longer OS (23.3 vs. 9.8 months; HR, 0.62; 95% CI, 0.34–1.05; <i>p</i> = .085). ARID1A status did not affect OS in the overall group or in the group that received GEM as the first-line regimen (<i>p</i> = .41 and <i>p</i> = .31, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Collectively, the current findings suggest that GEM, particularly as a first-line treatment, may improve the prognosis of patients with PR-OCCC. Moreover, Bev combination therapy is a promising option for treating PR-OCCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NCCN guidelines focus on treatment options for patients with multiple myeloma","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.70014","DOIUrl":"10.1002/cncr.70014","url":null,"abstract":"&lt;p&gt;The National Comprehensive Cancer Network (NCCN) recently published significant updates specific to treatment options for patients with newly diagnosed multiple myeloma (MM) who are eligible or ineligible for hematopoietic cell transplantation (HCT), recommendations for maintenance therapy, and treatment options for previously treated MM.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Based on the most recent clinical evidence, the recommendations are meant to serve as guidelines, and clinicians are encouraged to use their best judgment when applying the recommendations in the context of individual clinical circumstances.&lt;/p&gt;&lt;p&gt;Ajay K. Nooka, MD, MPH, associate director of clinical research at the Winship Cancer Institute at Emory University in Atlanta, Georgia, points to several new updates for oncologists.&lt;/p&gt;&lt;p&gt;Patients who do not meet the criteria for high risk are considered to be at standard risk.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;New updates for the diagnostic workup of MM include renal biopsy for albuminuria or abnormal renal function and the addition of next-generation sequencing for &lt;i&gt;TP53&lt;/i&gt; mutation assessment. The updates also include a revised recommendation for baseline clonotype identification at diagnosis and for the storage of an aspirate sample for future clonotype identification to enable minimal residual disease testing through next-generation sequencing.&lt;/p&gt;&lt;p&gt;The update added daratumumab as a high-risk treatment option based on evidence from the phase 3 AQUILA trial showing that patients treated with subcutaneous daratumumab had a significantly lower risk of progression to active MM.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The updated recommendations call for the addition of central nervous system disease management, including multimodality therapy, radiation, intrathecal chemotherapy, and systemic chemotherapy, and novel agents such as chimeric antigen receptor (CAR) T-cell therapy.&lt;/p&gt;&lt;p&gt;For primary therapy in patients who are candidates for HCT, the update recommends the quadruple regimen of isatuximab-irfc, bortezomib, lenalidomide, and dexamethasone (Isa-VRd).&lt;/p&gt;&lt;p&gt;For primary therapy in patients for whom HCT is deferred or who are not candidates for HCT, the update recommends either daratumumab, bortezomib, lenalidomide, and dexamethasone or Isa-VRd for patients who are &lt;80 years old and are not frail. Dr Nooka emphasizes that all the treatment recommendations are based on the strongest (category 1) evidence.&lt;/p&gt;&lt;p&gt;The recommendations provide guidance on the treatment of patients in certain circumstances. Patients can receive more than one B-cell maturation antigen (BCMA)–targeted therapy, although the optimal sequencing of sequential BCMA-targeted therapies is not known. Dr Nooka emphasizes, however, that accumulated data suggest that immediately following with the second BCMA-directed therapy after relapse may be associated with lower response rates.&lt;/p&gt;&lt;p&gt;Other circumstances include the use of belantamab mafodotin-blmf (as available ","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non–small cell lung cancer","authors":"Long Huang MD,&nbsp;Fanxu Zeng MD,&nbsp;Peng Huang MD,&nbsp;Dou Ren MD,&nbsp;Zhiqi Liu MD,&nbsp;Hanlin Chen MSc,&nbsp;Xiaoying Wu MSc,&nbsp;Jiaohui Pang MSc,&nbsp;Qiuxiang Ou PhD,&nbsp;Xiaotian Zhao MSc,&nbsp;Hua Bao PhD,&nbsp;Chengchuan Jiang MD,&nbsp;Nong Yang PhD","doi":"10.1002/cncr.70063","DOIUrl":"10.1002/cncr.70063","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non–small cell lung cancer (NSCLC) patients with <i>EGFR</i> L833 and H835 mutations show potentially satisfying responses to EGFR tyrosine kinase inhibitors (TKI); however, investigations on their molecular and clinical characteristics are limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>DNA sequencing data from 240 NSCLC patients with <i>EGFR</i> L833 and H835 mutations were analyzed, including 57 with EGFR-TKI treatment records. An external cohort of 346 <i>EGFR</i> L858R-mutated NSCLC patients was also evaluated for comparative molecular landscape analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the study cohort, 98.3% of patients with <i>EGFR</i> L833 mutations and 100% with <i>EGFR</i> H835 mutations had concurrent <i>EGFR</i> mutations. A total of 97.5% of patients (78 of 80) with <i>EGFR</i> H835L mutations had concurrent L833V mutations, whereas the most frequent comutations of <i>EGFR</i> L833V were L858R (44.1%) and H835L (37.0%). Compared to <i>EGFR</i> L858R patients in the external cohort, those with <i>EGFR</i> L833V+H835L and L833V+L858R mutations had less frequent <i>LRP1B</i>, <i>RB1</i>, <i>TP53</i> mutations, <i>CD4K</i> amplifications, and mutations in the RTK-RAS and cell-cycle signaling pathways. Tumor mutational burden, chromosomal instability, and whole-genome duplication rates were lower in these patients compared to those with classical <i>EGFR</i> L858R. Notably, patients with <i>EGFR</i> L833 and H835 mutations achieved a median progression-free survival (PFS) of 16.4 months, similar to patients with classical <i>EGFR</i> mutations. PFS was comparable across mutation subtypes and different generations of EGFR-TKIs received.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study highlights the unique molecular characteristics of NSCLC patients with <i>EGFR</i> L833 and H835 mutations and confirms their sensitivity to all generations of EGFR-TKIs, with PFS comparable to L858R, providing real-world evidence for clinical decision-making.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.70012","DOIUrl":"10.1002/cncr.70012","url":null,"abstract":"&lt;p&gt;Waiting for at least 3 months to assess the prostate-specific antigen (PSA) level after radical prostatectomy may minimize overtreatment in some patients according to the results of a study published in &lt;i&gt;JAMA Oncology&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;A conventional assessment of the PSA level typically occurs 1.5–2.0 months after radical prostatectomy, but data on the serum half-life of total PSA after radical prostatectomy suggest that it may take longer for clearance of PSA from the serum, particularly in patients with higher PSA levels before surgery.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Investigators in the current study evaluated how long to monitor PSA after radical prostatectomy to accurately document persistent PSA. They also looked at whether an increasing level of PSA predicts worse outcomes.&lt;/p&gt;&lt;p&gt;Using databases from two academic health centers, investigators identified 43,298 patients with T1N0M0 to T3N0M0 prostate cancer who were treated with radical prostatectomy between 1992 and 2020: 30,461 of the patients were included in the initial discovery cohort, and 12,837 were included in a subsequent validation cohort.&lt;/p&gt;&lt;p&gt;The study evaluated whether a significant interaction existed between a PSA level greater than 20 ng/mL versus 20 ng/mL or less before radical prostatectomy and a persistent PSA level versus undetectable PSA after radical prostatectomy with respect to prostate cancer-specific mortality (PCSM) risk and all-cause mortality (ACM) risk. The analysis was adjusted for all known prostate cancer prognostic factors.&lt;/p&gt;&lt;p&gt;Investigators found that among patients with a persistent PSA level after radical prostatectomy, a presurgery PSA level greater than 20 ng/mL versus 20 ng/mL or less was significantly associated with reduced ACM risk and PCSM risk. The association remained after adjusting for the prostate gland volume. The PCSM finding was confirmed in the validation cohort.&lt;/p&gt;&lt;p&gt;Investigators said the “counterintuitive” finding may be explained by a higher proportion of patients with a preradical prostatectomy PSA level greater than 20 ng/mL versus 20 ng/mL or less who would have been observed to have reached an undetectable PSA level with longer PSA assessment.&lt;/p&gt;&lt;p&gt;The study also found that patients with an increasing persistent PSA level after radical prostatectomy had a significantly increased ACM risk (adjusted hazard ratio [aHR], 1.14; 95% CI, 1.04–1.24; &lt;i&gt;p&lt;/i&gt; = .004) and PCSM risk (aHR, 1.27; 95% CI, 1.12–1.45; &lt;i&gt;p&lt;/i&gt; &lt; .001).&lt;/p&gt;&lt;p&gt;The senior author of the study, Anthony D’Amico, MD, a professor of radiation oncology at Harvard Medical School and chief of genitourinary radiation oncology at the Brigham and Women’s Hospital and Dana-Farber Brigham Cancer Center in Boston, Massachusetts, underscores the importance of waiting for 3 months after surgery before ascertaining whether the PSA level is persistent. “If the PSA level is still detectable at three months, repeating another PSA within the next month w","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The legend of the response evaluation criteria in solid tumors: A historical overview","authors":"Illaa Smesseim MD,&nbsp;Kevin B. W. Groot Lipman PhD,&nbsp;Ferry Lalezari MD,&nbsp;Jacobus A. Burgers MD, PhD,&nbsp;Stefano Trebeschi PhD","doi":"10.1002/cncr.70064","DOIUrl":"10.1002/cncr.70064","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this review, the historical development of tumor response criteria is examined and an interview was conducted with one of the original researchers behind the original study. This study, published nearly five decades ago, assessed tumor size through palpation and measurements of simulated tumor masses (“balls under mattresses”). The methodology used in that early study as well as in subsequent research that has influenced modifications of the current response evaluation criteria was critically evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The current tumor response criteria trace back to a 1976 study by Moertel and Hanley, which relied on palpation to measure tumor size. The key outcome, a 50% reduction in the product of the longest perpendicular diameters of the most measurable tumor mass, formed the basis for later criteria. The World Health Organization criteria adopted these thresholds for response and introduced a 25% increase as a cutoff for progression. Later, unidimensional measurements replaced two-dimensional ones, with adjusted thresholds accordingly. These criteria further inspired the development of specialized response criteria such as Choi, mRECIST, and PERCIST.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>By analyzing the evolution of RECIST, it is highlighted that these criteria are not fixed standards but rather the product of a series of pragmatic choices and compromises rooted in their historical context. With advances in technology, including artificial intelligence and volumetric imaging, it is timely to reassess the reliability of current criteria and explore new approaches to tumor response evaluation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine","authors":"Jiaying Lian MSM,&nbsp;Xianxu Zhuang MSM,&nbsp;Ying Chen MSM,&nbsp;Qingqing Lin MSM,&nbsp;Renzhi Pei MD,&nbsp;Dong Chen MD,&nbsp;Shuangyue Li MSM,&nbsp;Peipei Ye MSM,&nbsp;Junjie Cao MSM,&nbsp;Jiaojiao Yuan MSM,&nbsp;Xiaowei Shi MSM,&nbsp;Xuhui Liu MD,&nbsp;Ying Lu MSM","doi":"10.1002/cncr.70053","DOIUrl":"10.1002/cncr.70053","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Venetoclax (VEN) in combination with azacitidine (AZA) (VEN-AZA) is used to treat acute myeloid leukemia (AML) in patients who are not candidates for intensive chemotherapy but research on prognostic factors remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Measurable residual disease (MRD) by multiparametric flow cytometry in AML is important but there is limited evidence of the clinical utility of monitoring MRD in patients treated with VEN-AZA. Herein, a total of 75 patients newly diagnosed with AML treated with VEN-AZA were retrospectively analyzed to examine the role and timing of MRD to predict survival. MRD enabled the categorization of patients into two groups: Day 14 MRD, &gt;1% (MRD^14-pos); and Day 14 MRD, ≤1% (MRD^14-neg).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 75 patients, 31 (41.3%) had MRD^14-neg, whereas 30 (40.0%) had not achieved complete remission (CR) after induction. MRD^14-neg was associated with improved overall survival (OS) (<i>p</i> = .024) and event-free survival (EFS) (<i>p</i> = .044). In addition, MRD^14-neg (<i>p</i> = .002 for both OS and EFS), <i>CSF3R</i> negative (<i>CSF3R</i>^neg) (<i>p</i> &lt; .001 for both OS and EFS), and transplantation (<i>p</i> = .005 for OS; <i>p</i> = .007 for EFS) were associated with improved survival outcomes. Further subgroup analysis revealed that MRD^14-pos patients who underwent transplantation showed a trend toward longer OS and EFS (<i>p</i> &lt; .001 for both).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Results in the MRD^14-neg group were better than in the MRD^14-pos group, and the prognosis for patients with AML was better when there was <i>CSF3R</i>^neg and transplantation. Additionally, for patients with AML with MRD^14-pos, consolidation with transplantation may increase survival.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144897638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024","authors":"Narjust Florez MD,&nbsp;Sandip Patel MD,&nbsp;Heather A. Wakelee MD,&nbsp;Julia Rotow MD,&nbsp;Elaine Shum MD,&nbsp;Jacob Sands MD,&nbsp;Ravi Salgia MD, PhD,&nbsp;Fred R. Hirsch MD, PhD,&nbsp;Solange Peters MD, PhD,&nbsp;Joshua Sabari MD,&nbsp;Hatim Husain MD,&nbsp;Lyudmila Bazhenova MD,&nbsp;Erminia Massarelli MD, PhD, MS,&nbsp;Leah M. Backhus MD, MPH,&nbsp;Percy Lee MD,&nbsp;Roy S. Herbst MD, PhD,&nbsp;Christine Bestvina MD,&nbsp;Kristin Higgins MD,&nbsp;Aakash Desai MD, MPH,&nbsp;Martin Dietrich MD, PhD,&nbsp;Hari Balaji Keshava MD, MS,&nbsp;Balazs Halmos MD, MS,&nbsp;David R. Gandara MD,&nbsp;Jonathan Wesley Riess MD, MS,&nbsp;Ana I. Velázquez MD, MSc,&nbsp;Anjali Sibley MD, MPH,&nbsp;Misty Shields MD, PhD,&nbsp;Triparna Sen PhD, MS,&nbsp;Edward S. Kim MD, MBA","doi":"10.1002/cncr.70060","DOIUrl":"10.1002/cncr.70060","url":null,"abstract":"<p>Clinical practice guidelines for nonsmall cell lung cancer (NSCLC) and small cell lung cancer include recommendations based on high-level clinical trial evidence, but complex clinical questions are frequently seen in real-world practice that are not clearly answered by prospective trial data. To address these questions, the <i>Bridging the Gaps Lung Cancer Consensus Conference 2024</i> (BtG LCCC 2024) convened to develop US-focused expert guidance for clinical situations in which level 1 evidence is lacking. At BtG LCCC 2024, a multidisciplinary expert panel discussed ongoing clinical issues in small cell lung cancer management, targeted therapy in <i>EGFR</i>-mutated NSCLC, management of early stage NSCLC, identification and management of non-<i>EGFR</i> oncogene-driven NSCLC, and use of immunotherapy in advanced/metastatic NSCLC. By using a modified Delphi process, 12 consensus recommendations were developed with the goal of providing guidance on the use of novel diagnostic methods and treatments for clinicians who manage lung cancer. This report reviews these areas of consensus and discusses ongoing questions about ways to apply current clinical evidence.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144897324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding quality of life under talquetamab: Learning to measure what matters","authors":"Lisa Leypoldt MD,&nbsp;Meral Beksac MD,&nbsp;Aurore Perrot MD","doi":"10.1002/cncr.70072","DOIUrl":"10.1002/cncr.70072","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 17","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144897504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}